Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

This publication has 21 references indexed in Scilit:

• [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics
  American Journal of Psychiatry, 1996
• [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
  Neurology, 1996
• The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study
  Life Sciences, 1995
• Risperidone in the treatment of schizophrenia
  American Journal of Psychiatry, 1994
• Positron emission tomographic imaging of the dopamine transporter with ¹¹C‐WIN 35,428 reveals marked declines in mild Parkinson's disease
  Annals of Neurology, 1993
• Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine
  Archives of General Psychiatry, 1992
• Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics
  The Lancet, 1992
• The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis: An open dose-finding study
  Schizophrenia Research, 1989
• Peracetic acid as a superior oxidant for preparation of [¹²³I]IBZM: A potential dopamine D‐2 receptor imaging agent
  Journal of Labelled Compounds and Radiopharmaceuticals, 1989
• Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs
  Archives of General Psychiatry, 1988